sábado, 18 de agosto de 2018

Fluconazole-Resistant Candida parapsilosis Bloodstream Isolates with Y132F Mutation in ERG11 Gene, South Korea - Volume 24, Number 9—September 2018 - Emerging Infectious Diseases journal - CDC

Fluconazole-Resistant <em>Candida parapsilosis</em> Bloodstream Isolates with Y132F Mutation in <em>ERG11</em> Gene, South Korea - Volume 24, Number 9—September 2018 - Emerging Infectious Diseases journal - CDC





Volume 24, Number 9—September 2018

Research Letter

Fluconazole-Resistant Candida parapsilosis Bloodstream Isolates with Y132F Mutation in ERG11 Gene, South Korea

Yong Jun Choi1, Yae-Jean Kim1, Dongeun Yong, Jung-Hyun Byun, Taek Soo Kim, Yun Sil Chang, Min Ji Choi, Seung Ah Byeon, Eun Jeong Won, Soo Hyun Kim, Myung Geun Shin, and Jong Hee ShinComments to Author 
Author affiliations: Chonnam National University Medical School, Gwangju, South Korea (Y.J. Choi, M.J. Choi, S.A. Byeon, E.J. Won, S.H. Kim, M.G. Shin, J.H. Shin)Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea (Y.-J. Kim, Y.S. Chang)Yonsei University College of Medicine, Seoul (D. Yong, J.-H. Byun)Seoul National University Hospital, Seoul (T.S. Kim)

Abstract

We recently observed the emergence of fluconazole-resistant Candida parapsilosis bloodstream isolates harboring a Y132F substitution in Erg11p in South Korea. These Y132F isolates had a higher propensity to cause clonal transmission than other fluconazole-resistant isolates and persisted within hospitals for several years, as revealed by microsatellite typing.
Candida parapsilosis is the second most common species isolated from patients with Candida bloodstream infections (BSIs) in Latin America and eastern Asia (1,2). Although uncommon, fluconazole-resistant C. parapsilosis isolates harboring the Y132F substitution in Erg11p (referred to as Y132F isolates) have been reported in Brazil, the United States, and Kuwait (36). The precise reason for the emergence of C. parapsilosis Y132F isolates has yet to be defined; it may be related to selective drug pressure, and the mutation at position 132 may be a hot spot for resistance mediated by ERG11, a gene encoding the azole target (3). Alternatively, C. parapsilosis Y132F isolate emergence may be associated with exogenous clonal transmission (4). We recently observed the emergence and nosocomial spread of Y132F isolates in South Korea. In this study, we report a greater increase in the clonal spread of C. parapsilosis Y132F BSI isolates than of non-Y132F fluconazole-resistant isolates within hospitals during the past several years.
We assessed the first 47 C. parapsilosis BSI isolates that were fluconazole-resistant (MIC ≥8 mg/L) according to the Clinical and Laboratory Standards Institute (CLSI) species-specific clinical breakpoint (7,8). All 47 isolates were obtained from multicenter surveillance cultures from 8 university hospitals (A–H) during 2005–2016. For all fluconazole-resistant isolates, we examined genotypic relationships using microsatellite typing. We defined >2 isolates with identical genotypes according to microsatellite typing as clonal isolates. We sequenced the ERG11 gene and 3 transcription factor genes: TAC1, which can lead to the upregulation of CDRMRR1, which can lead to the upregulation of MDR; and UPC2, which can lead to the upregulation of ERG11(5); we compared the results with those of 20 fluconazole-susceptible (MIC 0.5–2 mg/L) isolates. This study was approved by the Institutional Review Board of Chonnam National University Hospital (IRB CNUH-2014-290).
Of the 47 C. parapsilosis fluconazole-resistant isolates, 30 (63.8%) had the Y132F substitution in Erg11p; however, none of the 20 fluconazole-susceptible isolates had the Y132F mutation in ERG11. Recently, 31%–57% of fluconazole-resistant C. parapsilosis isolates from different parts of the world were reported to be Y132F isolates, but the Y132F mutation was absent in all fluconazole-susceptible isolates (36). These data confirm that a Y132F substitution in Erg11p is the predominant fluconazole resistance mechanism for C. parapsilosis worldwide.
Microsatellite typing revealed that 4 clonal Y132F isolates (M1–4) were persistently recovered in 2 hospitals (A and B) over a period of 3–7 years, and the proportion of clonal isolates was much higher in Y132F isolates (86.7%, 26/30) than in non-Y132F fluconazole-resistant isolates (11.8%, 2/17) (Table). In a previous microsatellite study from a US surveillance study by Grossman et al. (4), no hospital specificity was detected among 13 non-Y132F fluconazole-resistant isolates; however, 2 notable clusters of isolates from 17 Y132F isolates were found over 8- or 18-month periods. The results obtained in our study and those of Grossman et al. indicate that Y132F isolates may have a higher propensity to cause clonal transmission and persist in particular hospitals than do non-Y132F fluconazole-resistant isolates. The Y132F substitution in Erg11p has also been detected in C. auris isolates from Pakistan (10/16 isolates), India (12/17 isolates), and Venezuela (5/5 isolates); these isolates are strongly associated with clonal transmission (9). Further studies are needed to determine whether the Y132F mutation in Erg11p has a direct effect on clonal transmission of C. parapsilosis or C. auris isolates.
Two previous studies conducted in the United States detected the Erg11p Y132F substitution in combination with the Erg11p R398I substitution in almost all C. parapsilosis BSI isolates (4,5). In addition, no Y132F isolates detected in a US surveillance study contained an MRR1 polymorphism, according to MRR1 sequence analysis results (4). However, a single Y132F substitution in Erg11p was found in all 30 fluconazole-resistant isolates from South Korea hospitals. The same K177N substitution in Mrr1p was found in all Y132F isolates except 1; none of the Y132F isolates showed missense mutations in Tac1p or Upc2p (Table). Taken together, these findings demonstrate low genetic diversity among Y132F isolates from the same country (the United States or South Korea).
In our study, 76.7% (23/30) of patients with Y132F isolates had no antifungal exposure within 30 days before candidemia detection, and their clonal transmission was not detected by routine hospital surveillance, partly because more than half of the patient hospitalizations did not overlap. These findings indicate that clonal Y132F isolates may be dormant over long periods and can survive and persist outside their host on hospital environmental surfaces, which may be similar to the behavior of C. auris (10). Although our study was limited by the relatively low number of isolates, our data suggest that C. parapsilosis Y132F isolates should be identified in clinical microbiology laboratories to prevent further clonal transmission of BSI caused by Y132F isolates.
Dr. Y.J. Choi is a clinical pathologist at Chonnam National University Hospital, Gwangju, South Korea. His current research interest is molecular epidemiology of fungal infections.
 Top

Acknowledgment

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education (NRF-2016R1A2B4008181).
 Top

References

  1. Pfaller  MAJones  RNDoern  GVSader  HSMesser  SAHouston  Aet al.The SENTRY Participant GroupBloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother2000;44:74751DOIPubMed
  2. Sandven  PEpidemiology of candidemia. Rev Iberoam Micol2000;17:7381.PubMed
  3. Souza  ACFuchs  BBPinhati  HMSiqueira  RAHagen  FMeis  JFet al. Candida parapsilosis resistance to fluconazole: molecular mechanisms and in vivo impact in infected Galleria mellonellalarvae. Antimicrob Agents Chemother2015;59:65817DOIPubMed
  4. Grossman  NTPham  CDCleveland  AALockhart  SRMolecular mechanisms of fluconazole resistance in Candida parapsilosis isolates from a U.S. surveillance system. Antimicrob Agents Chemother2015;59:10307DOIPubMed
  5. Berkow  ELManigaba  KParker  JEBarker  KSKelly  SLRogers  PDMultidrug transporters and alterations in sterol biosynthesis contribute to azole antifungal resistance in Candida parapsilosis. Antimicrob Agents Chemother2015;59:594250DOIPubMed
  6. Asadzadeh  MAhmad  SAl-Sweih  NKhan  ZEpidemiology and molecular basis of resistance to fluconazole among clinical Candida parapsilosis isolates in Kuwait. Microb Drug Resist2017;23:96672DOIPubMed
  7. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts—third edition: approved standard (M27–A3). Wayne (PA): The Institute; 2008.
  8. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts: fourth informational supplement (M27–S4). Wayne (PA): The Institute; 2012.
  9. Lockhart  SREtienne  KAVallabhaneni  SFarooqi  JChowdhary  AGovender  NPet al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis2017;64:13440DOIPubMed
  10. Welsh  RMBentz  MLShams  AHouston  HLyons  ARose  LJet al. Survival, persistence, and isolation of the emerging multidrug-resistant pathogenic yeast Candida auris on a plastic health care surface. J Clin Microbiol2017;55:29963005DOIPubMed
 Top

Table

 Top
Cite This Article

DOI: 10.3201/eid2409.180625
Original Publication Date: 7/31/2018
1These authors contributed equally to this article.

2 comentarios:

  1. Am One of the happiest woman on earth since my son was cured from the problem of seizure,which he has been having for eight years now,he do have the attack two to three times a week,which was affecting his education and his life.i got the contact of doctor Williams from the post of one Mr Paul thanking him for curing his seizure problem,i got the contact and contacted him then he made me to know that the medication is a permanent cure, and that was how i got the medication which i used on my son,and for six month now there have been no sign of seizure in him again.any one with such problem can contact him on his email on drwilliams098675@gmail.com for more information.

    ResponderEliminar
  2. WOW ALL THANKS TO DR WILLIAMS I HAVE NEVER BELIEVE IN HERBAL REMEDIES.  my son have been a patient of epilepsy . I had tried a lot of anti viral med prescribed to me by doctors over how many years now but I could not see any improvements in my son symptoms. One day when going through the internet , i got to know about this great Herbal Dr who uses his herbal remedies in curing people from epilepsy,quickly i contacted him and he prepared a herbal medication for my son which i received and he used it as instructed by dr williams. After few weeks the improvement were very visible. the sleepiness and the abnormal behavior stooped ,on thing now he is so full of life. I would recommend this to all my friends,families,around the globe suffering from epilepsy.you can contact him through his email on drwilliams098675@gmail.com.for advice and for his product THANKS TO YOU ONCE AGAIN DR WILLIAMS

    ResponderEliminar